<DOC>
	<DOCNO>NCT01000376</DOCNO>
	<brief_summary>The purpose study investigate whether ketoconazole , take orally , influence level eribulin blood two drug give time . The study enroll patient solid tumor whose cancer become bad even standard treatment , standard treatment available . The study also investigate whether eribulin give together ketoconazole safe ( side-effects ) effective cancer .</brief_summary>
	<brief_title>Evaluating Pharmacokinetics Tolerance Co-administration Oral Multiple Dose Ketoconazole IV ( Bolus ) Infusion Eribulin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm advanced solid tumor progress follow standard therapy standard therapy exists ( include surgery radiation therapy ) . 2 . Resolution chemotherapy radiationrelated toxicity Grade 1 severity low , except stable sensory neuropathy ≤ Grade 2 alopecia . 3 . Patients must age ≥ 18 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 5 . Life expectancy ≥ 3 month . 6 . Patients must adequate renal function evidence serum creatinine ≤ 2.0 mg/dL ( ≤ 176 mol/L ) calculate creatinine clearance ≥ 40 mL/minute ( min ) per Cockcroft Gault formula . 7 . Patients must adequate hepatic function evidence bilirubin ≤ 1.5 time upper limit normal ( ULN ) alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 3 time ULN , ( case liver metastases ≤ 5 time ULN case bone metastasis , liver specific alkaline phosphatase ≤ 3 time ULN ) . 8 . Patients must adequate bone marrow function evidence absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L , hemoglobin ≥ 10.0 g/dL ≥ 6.2 mmol/L ( hemoglobin &lt; 10.0 g/dL &lt; 6.2 mmol/L acceptable correct growth factor transfusion ) , platelets ≥ 100 x 10^9/L . 9 . Patients must willing able comply study protocol duration study . 10 . Patients must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . 1 . Patients receive follow treatment within specified period eribulin treatment start : 1 . Chemotherapy , radiation biological therapy within 2 week . 2 . Hormonal therapy within 1 week . 3 . Any investigational drug within 4 week . 2 . Patients receive anticoagulant therapy warfarin related compound , line patency change heparinbased therapy , eligible . If patient continue minidose warfarin , prothrombin time ( PT ) international normalize ratio ( INR ) must closely monitor . 3 . Patients receive , time study start , medication , dietary supplement compound substance know induce inhibit CYP3A4 activity , exception ketoconazole . A comprehensive list find http : //medicine/iupui.edu/flockhart/table.htm . 4 . Patients use ketoconazole contraindicate . 5 . Patients receive drug might influence ketoconazole metabolism . 6 . Women pregnant breastfeeding ; woman childbearing potential either positive pregnancy test screening pregnancy test ; woman childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 7 . Fertile men willing use contraception fertile men female partner willing use contraception . 8 . Patients whose intestinal absorption impair . 9 . Severe/uncontrolled intercurrent illness/infection . 10 . Significant cardiovascular impairment ( history congestive heart failure &gt; New York Heart Association ( NYHA ) Grade II , unstable angina myocardial infarction within past 6 month , serious cardiac arrhythmia . 11 . Patients organ allograft require immunosuppression ( include blood blood component transfusion ) . 12 . Patients know positive human immunodeficiency virus ( HIV ) status . 13 . Patients brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least 4 week start treatment eribulin . 14 . Patients meningeal carcinomatosis . 15 . Patients hypersensitivity halichondrin B and/or halichondrin Blike compound . 16 . Patients preexist neuropathy &gt; Grade 2 . 17 . Patients significant disease disorder , Investigator 's opinion , would exclude patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>solid tumor</keyword>
</DOC>